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Introduction
IL-22 is a newly described IL-10 cytokine family member.
It mainly acts on epithelial cells and hepatocytes by inter-
acting with a membrane receptor. IL-22 has been shown
to have protective or deleterious effects on its targets cells
depending on the context. IL-22 has been implicated in
inflammatory bowel diseases (IBD) but its role still
remains unclear. IL-22 is increased in Crohn’s disease
(CD) but not in ulcerative colitis (UC). Furthermore IL-22
appears to have beneficial effects in several murine models
of IBD. IL-22BP is a soluble inhibitory receptor specific for
IL-22 whose physiological role and regulation are mainly
unknown during inflammatory conditions.
Aims
To assess the regulation of IL-22BP during IBD.
Methods
Colonic biopsies were obtained from patients with active
CD or UC. Biopsies were made in inflammatory and non-
inflammatory mucosa for both conditions. Patients with
polyps were used as healthy controls. IL-22BP mRNA
expression was assessed by q-PCR and confirmed at the
protein level by immunohistology, using a monoclonal Ab
to IL-22BP. Informed consent was obtained from all the
patients.
Results
No difference could be observed in the IL-22BP mRNA
expression between the non inflammatory mucosa of CD
or UC patients compared with healthy controls. In UC
patients, IL-22BP was expressed at the same level in
inflammatory or non inflammatory samples. In contrast,
important up-regulation of IL-22BP mRNA expression was
detected in the inflammatory mucosa of CD patients as
compared to non inflammatory samples. This upregulation
was confirmed at the protein level by immunostaining
experiments. IL-22BP was mostly detected in the lamina
propria of the colon. In UC patients, IL-22BP protein
exhibited actually a diminished expression as compared to
controls.
Conclusion
Taken together these results highlight a different
profile of IL-22BP production during CD and UC.
Up-regulation of IL-22BP during CD is probably con-
comitant to IL-22 up-regulation already described, sug-
gesting an immunomodulatory function of IL-22BP
specific to CD.
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